ENTREMED BEGINS CLINICAL TRIALS OF PANZEM NCD IN PATIENTS WITH ADVANCED CANCER

EntreMed has commenced Phase Ib clinical trials to evaluate the pharmacokinetic properties and safety of Panzem NCD, its next generation formulation of its lead product candidate, Panzem (2-methoxyestradiol or 2ME2).

Advanced cancer patients whose disease has failed to respond to existing therapies or where no approved therapy is available are expected to be enrolled in the studies. The purpose of the dose escalation studies will be to evaluate the pharmacokinetics and safety of Panzem NCD.